Show simple item record

dc.contributor.authorMcDowell, Ronald
dc.contributor.authorBennett, Kathleen
dc.contributor.authorMoriarty, Frank
dc.contributor.authorClarke, Sarah
dc.contributor.authorBarry, Michael
dc.contributor.authorFahey, Tom
dc.date.accessioned2018-05-02T15:44:04Z
dc.date.available2018-05-02T15:44:04Z
dc.date.issued2018-04-20
dc.identifier.citationAn evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011-2016): an interrupted time-series study. 2018, 8 (4):e019315 BMJ Openen
dc.identifier.issn2044-6055
dc.identifier.pmid29678966
dc.identifier.doi10.1136/bmjopen-2017-019315
dc.identifier.urihttp://hdl.handle.net/10147/622978
dc.descriptionTo examine the impact of the Preferred Drugs Initiative (PDI), an Irish health policy aimed at enhancing evidence-based cost-effective prescribing, on prescribing trends and the cost of prescription medicines across seven medication classeen
dc.description.abstractTo examine the impact of the Preferred Drugs Initiative (PDI), an Irish health policy aimed at enhancing evidence-based cost-effective prescribing, on prescribing trends and the cost of prescription medicines across seven medication classes.
dc.description.abstractRetrospective repeated cross-sectional study spanning the years 2011-2016.
dc.description.abstractHealth Service Executive Primary Care Reimbursement Service pharmacy claims data for General Medical Services (GMS) patients, approximately 40% of the Irish population.
dc.description.abstractAdults aged ≥18 years between 2011 and 2016 are eligible for the GMS scheme.
dc.description.abstractThe percentage of PDI medications within each drug class per calendar quarter. Linear regression was used to model prescribing of the preferred drug within each medication group and to assess the impact of PDI guidelines and other relevant changes in prescribing practice. Savings in drug expenditure were estimated.
dc.description.abstractBetween 2011 and 2016, around a quarter (23.59%) of all medications were for single-agent drugs licensed in the seven drug classes. There was a small increase in the percentage of PDI drugs, increasing from 4.64% of all medications in 2011 to 4.76% in 2016 (P<0.001). The percentage of preferred drugs within each drug class was significantly higher immediately following publication of the guidelines for all classes except urology, with the largest increases noted for lansoprazole (1.21%, 95% CI: 0.84% to 1.57%, P<0.001) and venlafaxine (0.71%, 95% CI: 0.15% to 1.27%, P=0.02). Trends in prescribing of the preferred drugs between PDI guidelines and the end of 2016 varied between drug classes. Total cost savings between 2013 and 2016 were estimated to be €2.7 million.
dc.description.abstractThere has been a small increase in prescribing of PDI drugs in response to prescribing guidelines, with inconsistent changes observed across therapeutic classes. These findings are relevant where health services are seeking to develop more active prescribing interventions aimed at changing prescribing practice.
dc.language.isoenen
dc.relation.urlhttp://bmjopen.bmj.com/content/bmjopen/8/4/e019315.full.pdfen
dc.rightsArchived with thanks to BMJ openen
dc.subjectPRESCRIBINGen
dc.subjectPRESCRIPTIONSen
dc.subject.otherMEDICINESen
dc.subject.otherCOSTen
dc.titleAn evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011-2016): an interrupted time-series study.en
dc.typeArticleen
dc.identifier.journalBMJ openen
refterms.dateFOA2018-08-30T15:51:58Z
html.description.abstractTo examine the impact of the Preferred Drugs Initiative (PDI), an Irish health policy aimed at enhancing evidence-based cost-effective prescribing, on prescribing trends and the cost of prescription medicines across seven medication classes.
html.description.abstractRetrospective repeated cross-sectional study spanning the years 2011-2016.
html.description.abstractHealth Service Executive Primary Care Reimbursement Service pharmacy claims data for General Medical Services (GMS) patients, approximately 40% of the Irish population.
html.description.abstractAdults aged ≥18 years between 2011 and 2016 are eligible for the GMS scheme.
html.description.abstractThe percentage of PDI medications within each drug class per calendar quarter. Linear regression was used to model prescribing of the preferred drug within each medication group and to assess the impact of PDI guidelines and other relevant changes in prescribing practice. Savings in drug expenditure were estimated.
html.description.abstractBetween 2011 and 2016, around a quarter (23.59%) of all medications were for single-agent drugs licensed in the seven drug classes. There was a small increase in the percentage of PDI drugs, increasing from 4.64% of all medications in 2011 to 4.76% in 2016 (P<0.001). The percentage of preferred drugs within each drug class was significantly higher immediately following publication of the guidelines for all classes except urology, with the largest increases noted for lansoprazole (1.21%, 95% CI: 0.84% to 1.57%, P<0.001) and venlafaxine (0.71%, 95% CI: 0.15% to 1.27%, P=0.02). Trends in prescribing of the preferred drugs between PDI guidelines and the end of 2016 varied between drug classes. Total cost savings between 2013 and 2016 were estimated to be €2.7 million.
html.description.abstractThere has been a small increase in prescribing of PDI drugs in response to prescribing guidelines, with inconsistent changes observed across therapeutic classes. These findings are relevant where health services are seeking to develop more active prescribing interventions aimed at changing prescribing practice.


Files in this item

Thumbnail
Name:
drug.pdf
Size:
1.493Mb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record